LIGAND PHARMACEUTICALS INCORPORATED
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $141.1M | $109.0M | $71.9M | $64.5M | $49.0M | $31.4M | $30.0M | $23.5M |
| Cost of Revenue | $5.4M | $5.6M | $5.8M | $9.1M | $5.7M | $3.6M | $4.9M | — |
| Gross Profit | $135.7M | $103.4M | $66.1M | $55.4M | $43.2M | $27.8M | $25.1M | — |
| Gross Margin | 96.2% | 94.9% | 91.9% | 85.8% | 88.3% | 88.5% | 83.7% | — |
| Operating Expenses | ||||||||
| Research & Development | $26.9M | $21.2M | $11.0M | $9.7M | $9.3M | $10.8M | $10.3M | $22.1M |
| SG&A Expense | $28.7M | $27.7M | $25.4M | $22.6M | $18.0M | $15.8M | $14.6M | $12.8M |
| Operating Income | $68.1M | $43.9M | $27.3M | $19.6M | $14.9M | $193.0K | $-878.0K | $-29.3M |
| Operating Margin | 48.2% | 40.3% | 38.0% | 30.4% | 30.5% | 0.6% | -2.9% | -124.5% |
| Interest Expense | $13.5M | $12.8M | — | $4.9M | $2.1M | $2.9M | $2.5M | $58.0K |
| Pretax Income | $57.2M | $8.0M | $35.3M | $11.3M | $9.2M | $-3.9M | $-3.6M | $-15.4M |
| Income Tax Expense | $44.7M | $10.3M | $-192.1M | $410.0K | $374.0K | $-1.2M | $-13.3M | $-2.6M |
| Net Income | $12.6M | $-1.6M | $229.8M | $12.0M | $11.4M | $-527.0K | $9.7M | $-10.4M |
| Net Margin | 8.9% | -1.5% | 319.6% | 18.6% | 23.3% | -1.7% | 32.3% | -44.1% |
| EPS (Basic) | $0.60 | $-0.08 | $11.61 | $0.59 | $0.56 | $-0.03 | $0.49 | $-0.53 |
| EPS (Diluted) | $0.53 | $-0.08 | $10.83 | $0.56 | $0.55 | $-0.03 | $0.49 | $-0.53 |
| Shares Outstanding (Basic) | 21.0M | 20.8M | 19.8M | 20.4M | 20.3M | 19.9M | 19.7M | 19.6M |
| Shares Outstanding (Diluted) | 23.5M | 20.8M | 21.2M | 21.4M | 20.7M | 19.9M | 19.7M | 19.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |